Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Ferris, Robert L., Licitra, Lisa, Fayette, Jerome, Even, Caroline, Blumenschein, George, Harrington, Kevin J., Guigay, Joel, Vokes, Everett E., Saba, Nabil F., Haddad, Robert, Ramkumar, Shanmugasundaram, Russell, Jeffery, Brossart, Peter, Tahara, Makoto, Colevas, A. Dimitrios, Concha-Benavente, Fernando, Lynch, Mark, Li, Li, Gillison, Maura L.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7721346/
https://ncbi.nlm.nih.gov/pubmed/31239321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3944
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars